Longbio Pharma (Suzhou) has reported positive topline results from a Phase I clinical trial of LP-003, a new long-acting anti-IgE antibody, for the treatment of allergic rhinitis.
The double-blind, randomised study has evaluated the pharmacokinetics, pharmacodynamics (free IgE levels) profile and safety of LP-003 in healthy subjects.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Subjects were randomised into five groups and administered intravenously with a single dose of 0. mg/kg, 1mg/kg, 3mg/kg, 6mg/kg and 10mg/kg, respectively.
A non-linear PK characteristic with T1/2 ranging from 46.3 days to 75.6 days was observed in patients, which is approximately 2～3 fold of omalizumab.
LP-003 also demonstrated high IgE binding affinity (>100 fold) without off-target binding and showed more potent FcεRI and FcεRII/CD23 inhibition in comparison with omalizumab.
Groups administered with 1 mg/Kg (except one with high baseline IgE level) to 10 mg/Kg showed suppression of free-IgE below the detection range for more than 70 days.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLP-003 showed a good safety profile with no Grade 3 and above TEAE.
Longbio Pharma co-founder and inventor of omalizumab Dr Sun, Nai-chau said: “The positive results reinforce our belief in the best-in-class potential of LP-003 and its ability to address the urgent needs of patients suffering from allergic diseases, like allergic rhinitis.”
Based on the positive data from the Phase I study, the company has started Phase II clinical trials of LP-003.
Longbio is also planning to collaborate with industry stakeholders for developing and marketing LP-003 globally.
A Phase II study of LP-003 in chronic spontaneous urticaria is also ongoing.
